BPC-157 vs TB-500: what is the difference?
Short answer
BPC-157 and TB-500 are both synthetic peptide fragments studied in animal models of tissue repair, but they come from different proteins: BPC-157 from a gastric protective protein, TB-500 from thymosin beta-4, an actin-binding protein. Neither has large human trials. Both are compounded medications, not FDA-approved, and both are prohibited in sport. They are prescribed together as the Wolverine Stack, or BPC-157 alone.
| Key difference | Different parent proteins and research angles: a gut-derived fragment versus an actin-binding fragment of thymosin beta-4 |
|---|---|
| BPC-157 | 15 amino acids, fragment of a protective protein in human gastric juice |
| TB-500 | 17 amino acids, actin-binding region of thymosin beta-4 (43 amino acids) |
| Evidence to date | Animal models and reviews for both; no large human trials of either; no trial of the pair |
| Form in this catalog | BPC-157 alone or blended with TB-500 (Wolverine Stack); injection, supplied already reconstituted |
| Regulatory status | Both compounded medications; neither FDA-approved for any use |
| Anti-doping | Both prohibited at all times (WADA, non-approved substances) |
| Study type | Sources |
|---|---|
| Human clinical trials | 0 |
| Other human studies | 0 |
| Animal and lab studies | 0 |
| Review articles | 4 |
What are BPC-157 and TB-500?
BPC-157 and TB-500 are often spoken of in one breath, and both are short synthetic peptides with animal-model repair research behind them, but they are unrelated molecules. BPC-157 is a 15-amino-acid fragment of a protective protein that researchers isolated from human gastric juice; it is stable in gastric acid, and its early research centered on the stomach and gut before moving to tendon, ligament and muscle.
TB-500 is a 17-amino-acid fragment of thymosin beta-4, a 43-amino-acid protein whose job inside cells is to bind actin, the building block of the internal scaffolding cells use to hold shape and to move. The fragment covers the actin-binding region, which is why TB-500 research is framed around cell migration rather than around the gut.
How do BPC-157 and TB-500 differ?
BPC-157 and TB-500 differ in origin, in the mechanisms the literature describes, and in how much of the research is actually about the compound itself. For BPC-157, the reviews are about BPC-157. For TB-500, much of the literature concerns the full thymosin beta-4 protein, and the fragment inherits that work by association. They also differ in how each shows up in this catalog: BPC-157 is prescribed by itself; TB-500 is only ever part of a blend.
| BPC-157 | TB-500 | |
|---|---|---|
| Length | 15 amino acids | 17 amino acids |
| Parent protein | Protective protein in human gastric juice | Thymosin beta-4 (43 amino acids) |
| Research angle | Tendon, ligament, muscle, bone and gut repair models; angiogenesis; nitric oxide pathway | Cell migration tied to actin binding; tissue repair models |
| Literature focus | Reviews about BPC-157 itself | Much of it about thymosin beta-4, the parent protein |
| Human trials | No large trials published | No large trials published |
| In this catalog | Alone, or in the Wolverine, Glow and KLOW stacks | Only inside the Wolverine, Glow and KLOW stacks |
| FDA status | Not approved; compounded | Not approved; compounded |
| WADA | Prohibited at all times (S0) | Prohibited at all times (S0) |
Get Wolverine Stack prescribed, pre-mixed
What does the research cover for each?
BPC-157 has the larger and more compound-specific literature. Reviews describe animal models, mostly in rats, of tendon, ligament, muscle and bone healing, of gut lesions and fistulas, and of new blood vessel formation, with interactions described in the nitric oxide system and with growth-factor signaling. One review compares it with standard angiogenic growth factors, which gives some sense of how its mechanism is framed.
TB-500 research is thinner and leans on its parent. The review in the references covers thymosin beta-4's basic properties and the clinical applications explored for the full protein; the animal and cell studies behind the fragment look at cell migration and tissue repair in injury models. Neither compound has a published, large, randomized human trial, and no study has tested the two together, so the common claim that they are 'synergistic' has no trial behind it.
How are BPC-157 and TB-500 prescribed?
BPC-157 and TB-500 are prescribed in the US only as compounded medications, written by a licensed provider for an individual patient and prepared by a licensed 503A pharmacy. Through Peptides.build, BPC-157 is available on its own as a subcutaneous injection, and the pair is available together as the Wolverine Stack, one vial with both peptides already reconstituted and each concentration on the label. TB-500 is not prescribed alone here.
Which route fits is decided at intake. The single compound is the simpler protocol with the deeper literature; the stack adds a second compound with its own animal data and a second variable to weigh. The BPC-157 calculator on this site converts a prescribed amount and a label strength into syringe units and has a blend mode for the Wolverine vial, but it does arithmetic only; the dose is set by the provider and never published on this site.
Are BPC-157 and TB-500 FDA-approved or allowed in sport?
BPC-157 and TB-500 share the same status: BPC-157 is not FDA-approved for any use, TB-500 is not FDA-approved for any use, both are prescribed only as compounded medications, and compounded medications are not FDA-approved. There is no approved product for either peptide behind the compounded version.
Both are prohibited at all times in sport. The World Anti-Doping Agency lists BPC-157 and TB-500 among non-approved substances, so the difference between them makes no difference to a drug-tested athlete, who should check with their governing body before considering either one or the stack.
Prescribed BPC-157 and TB-500 vs research peptides: what is different?
Prescribed BPC-157 and TB-500 are not research chemicals. They are prescription medications: a licensed US provider reviews your intake first, and a licensed 503A pharmacy compounds each one for you by name. Vials sold online as “research use only” skip both steps. What you pay for here is that review, a pharmacy you can name, and a label that says what is in the vial.
A research seller’s certificate of analysis is a document the seller controls: it chooses the lab and the sample, and a PDF can be reused, edited or re-dated. No regulator checks it.
| Point | Prescribed through Peptides.build | Research use only |
|---|---|---|
| Access | Online intake reviewed by a licensed US provider; prescribed only when appropriate. | No prescription and no clinical review of whether it suits you. |
| How it's labeled | A prescription medication compounded for you by name. | Commonly sold labeled “research use only, not for human consumption.” |
| Who prepares it | A licensed 503A US compounding pharmacy under state and federal oversight. | Unregulated suppliers, often with no verifiable chain of custody. |
| Testing | Third-party tested. | Certificates of analysis are self-reported when provided at all. |
| Purity and identity | Prepared to a prescription for a specific patient. | Purity, strength, and even identity are unverified by any independent party. |
This compares two care models, not two products. Compounded medications are not FDA-approved, and we do not claim otherwise. What a prescription adds is a licensed provider deciding whether a protocol is appropriate for you and a licensed pharmacy preparing it. Read the full guide to research vs prescription peptides.
BPC-157 vs TB-500 FAQ
Which is better, BPC-157 or TB-500?
No published study compares them, and neither has large human trials, so there is no evidence-based answer. They come from different proteins and are studied for different mechanisms; a provider decides whether one, both or neither fits your history.
Can BPC-157 and TB-500 be taken together?
They are prescribed together as the Wolverine Stack, a compounded blend of both in one vial. No trial of the combination has been published; the pairing rests on overlapping animal research.
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is a 43-amino-acid protein; TB-500 is a synthetic 17-amino-acid fragment containing its actin-binding region. Much of the published research is on the full protein.
Do BPC-157 and TB-500 have human trials?
Neither has a published, large, randomized human trial. BPC-157 has animal models and reviews; TB-500 has animal and cell work plus a review of its parent protein.
Are BPC-157 and TB-500 banned in sport?
Yes, both. The World Anti-Doping Agency lists each among prohibited non-approved substances, banned at all times. Drug-tested athletes should check with their governing body.
Are BPC-157 and TB-500 FDA-approved?
No. Neither BPC-157 nor TB-500 is FDA-approved for any use. Both reach patients only as compounded medications prescribed by a licensed provider, and compounded medications are not FDA-approved.
Wolverine Stack through Peptides.build
A licensed US provider reviews a short online intake and decides whether a protocol is appropriate. A US 503A pharmacy prepares it already reconstituted, labels the concentration and ships it cold-chain. Dosing is set by the provider and is not published on this site.
Start your Wolverine Stack visit · from $183/moReferences
- Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology, 2021. doi:10.3389/fphar.2021.627533Study type: Review
- BPC 157 and its Role in Accelerating Musculoskeletal Soft-Tissue Healing. Cell and Tissue Research, 2019. doi:10.1007/s00441-019-03016-8Study type: Review
- BPC 157 and Standard Angiogenic Growth Factors: Tendon, Ligament, Muscle and Bone Healing. Current Pharmaceutical Design, 2018. doi:10.2174/1381612824666180712110447Study type: Review
- Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 2012. doi:10.1517/14712598.2012.634793Study type: Review
Citations are listed with their study type so the evidence can be weighed. Review articles summarize other studies; animal and in vitro findings do not describe outcomes in people.
This article is educational and is not medical advice. Neither compound is FDA-approved for any use, and compounded medications are not FDA-approved. No results are implied or guaranteed. Talk to a licensed provider about your own history before starting any protocol.